Hikma Pharmaceuticals (OTCMKTS:HKMPF) Shares Gap Down - Time to Sell?

Key Points

• Hikma Pharmaceuticals shares experienced a significant **gap down**, opening at $23.52 after closing at $24.50, with the last trade recorded at $23.25.
• BNP Paribas initiated coverage with an **"outperform" rating**, contributing to the overall average rating of **"Buy"** for the stock.
• The company's current financial ratios include a **quick ratio of 0.72** and a **debt-to-equity ratio of 0.33**, indicating relatively stable liquidity and leverage positions.

Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF - Get Free Report)'s share price gapped down before the market opened on Tuesday . The stock had previously closed at $24.50, but opened at $23.52. Hikma Pharmaceuticals shares last traded at $23.25, with a volume of 640 shares changing hands.

Hikma Pharmaceuticals Trading Down 2.1%

The company has a 50-day simple moving average of $25.70 and a two-hundred day simple moving average of $26.51. The company has a current ratio of 1.24, a quick ratio of 0.72 and a debt-to-equity ratio of 0.33.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.